Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosas, A. L. Articles by Casadevall, A. Search for Related Content PubMed PubMed Citation Articles by Rosas, A. L. Articles by Casadevall, A.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2002, p. 144-148, Vol. 9, No. 1
1071-412X/01/$04.00+0     DOI: 10.1128/CDLI.9.1.144-148.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Activation of the Alternative Complement Pathway by Fungal Melanins

Á. L. Rosas,¹ R. S. MacGill,² J. D. Nosanchuk,^3* T. R. Kozel,² and A. Casadevall^1,3

Department of Microbiology and Immunology,¹ Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York,³ Department of Microbiology, School of Medicine, University of Nevada, Reno, Nevada²

Received 23 March 2001/ Returned for modification 23 July 2001/ Accepted 19 October 2001

Top Abstract Introduction Materials and Methods Results Discussion References

 
Melanins are complex biological pigments formed by the oxidative polymerization of phenolic and/or indolic compounds. These pigments have been implicated in the pathogenesis of some microbial infections, malignancies, degenerative disorders, and autoimmune diseases. Recent studies have demonstrated that melanins have antigenic and anti-inflammatory properties. These findings led us to further explore the interaction of melanins with the immune system. Melanin particles ("ghosts") were isolated from in vitro-melanized Cryptococcus neoformans cells and Aspergillus niger conidia and then incubated in normal human serum containing ¹²⁵I-labeled complement C3. The results demonstrated deposition of C3 fragments onto the melanin ghosts as early as 1 min after incubation, with maximum deposition occurring after 12 min for C. neoformans-derived melanin ghosts and after 25 min for A. niger-derived melanin ghosts. The blocking of classical pathway activation did not affect the kinetics or total deposition of C3 onto the melanin ghosts, indicating that melanins activate complement through the alternative pathway. Immunofluorescence analysis of lungs from BALB/c mice injected intratracheally with C. neoformans-derived melanin ghosts demonstrated deposition of C3 fragments onto the ghosts. Small granulomas were also observed surrounding the ghosts. However, melanization of the C. neoformans cell wall did not alter the kinetics or total deposition of C3 fragments onto the fungal cells. The finding that melanin surfaces can activate the complement system suggests a potential mechanism for the pathogenesis of some degenerative and/or autoimmune processes that involve melanized cells as well as another potential role for melanin in the virulence of melanin-producing microorganisms.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Melanins are negatively charged pigments with hydrophobic surfaces which are formed by the oxidative polymerization of phenolic and/or indolic compounds (5, 44). These pigments are synthesized by organisms representative of all biological kingdoms and have been implicated in a wide variety of physiological and pathological processes, including the pathogenesis of some microbial infections (5, 44), malignant melanoma (14, 34), Parkinson’s disease (9, 12, 45), traumatic anterior-chamber uveitis (3, 4, 18), and vitiligo (22, 43). Melanins are immunologically active, as they can induce strong T-cell-independent antibody responses in mice (27) and have anti-inflammatory properties (1, 25).

Cryptococcus neoformans is an encapsulated yeast-like fungus that has emerged as a leading pathogen in immunocompromised individuals, including 6 to 8% of patients with AIDS (24). There is strong evidence that C. neoformans synthesizes melanin during infection (28, 29, 36). In vitro experiments have shown that melanin is localized in the cryptococcal cell wall (39) and may contribute to virulence in part because of its ability to bind and neutralize oxidants (11, 15–17, 32, 42), microbicidal peptides (10), and antifungal drugs (41). Melanization also increases the negative charge of C. neoformans cells (26), which may contribute to the reduced susceptibility of melanized cells to phagocytosis by host effector cells (2, 39).

Components of the complement system play a critical role in resistance to cryptococcal infections, since the deposition of complement C3 fragments onto the polysaccharide capsule of C. neoformans cells is essential for optimal phagocytosis and clearance of the fungus (6–8, 19). Despite the immunological properties of melanins, the interaction of these pigments with the complement system has not been studied. The objectives of this study were to determine (i) whether natural melanins can interact with the complement system and (ii) whether the melanization of C. neoformans affects the activation of complement by the fungal cells. Our results demonstrated that melanins can activate the alternative complement pathway; however, melanization did not affect the kinetics or total deposition of C3 fragments onto C. neoformans cells.

(The data in this paper are from a thesis to be submitted by Á. L. Rosas in partial fulfillment of the requirements for the degree of doctor of philosophy in the Sue Golding Graduate Division of Medical Sciences, Albert Einstein College of Medicine, Yeshiva University, Bronx, N.Y.)

Top Abstract Introduction Materials and Methods Results Discussion References

 
Fungal cells. C. neoformans serotype D strains 3501 and 24067 and Aspergillus niger strain J9901 were purchased from the American Type Culture Collection (Manassas, Va.).

Melanization of fungal cells. C. neoformans 3501 was grown in a defined minimal medium (15 mM glucose, 10 mM MgSO₄, 29.4 mM KH₂PO₄, 13 mM glycine, 3 µM vitamin B₁; pH 5.5) with or without 1 mM L-3,4-dihydroxyphenylalanine (L-DOPA) (Sigma Chemical Co., St. Louis, Mo.) for 8 days at 30°C in a rotary shaker at 150 rpm. Only cells grown with L-DOPA became melanized. C. neoformans 24067 was grown for 15 days in minimal medium with L-DOPA.

A. niger was grown on Sabouraud dextrose agar (pH 5.6) (Difco Laboratories, Detroit, Mich.) for 5 months at 30°C to allow heavy melanization of the conidia.

Isolation of fungal melanins. Melanin was extracted from melanized C. neoformans 24067 cells and A. niger conidia by treatment with proteolytic and glycolytic enzymes, with a denaturant, by chloroform extractions, and with boiling HCl, as described previously (34). Melanin particles, also referred to as melanin "ghosts" (40), were collected by centrifugation, washed extensively, and dialyzed against distilled water for 10 days. Melanin ghosts were then washed and suspended in phosphate-buffered saline (PBS; pH 7.4). Although the purity of the melanin ghosts cannot be established unequivocally because of the lack of knowledge about the structure of any melanin, the melanins used in this study consistently gave the same C/N/O ratios for the same melanin after quantitative analyses carried out as described in reference 35, which strongly suggests that the preparations were free of other cellular components.

Serum and serum proteins. Blood was collected from at least 10 donors. The sera were isolated, pooled, and stored at -85°C until use. C3 was isolated from frozen human plasma as described previously (20, 38) and labeled with ¹²⁵I by using Iodogen (Pierce, Rockford, Ill.) according to the manufacturer’s instructions.

Kinetic analyses of C3 binding in vitro. The kinetics of activation and binding of C3 fragments to melanin ghosts or C. neoformans 3501 cells (melanized and nonmelanized) were assessed in 1-ml reaction mixtures consisting of (i) 40% normal human serum (NHS), (ii) GVB²⁺ (5 mM sodium Veronal-buffered saline [142 mM] [pH 7.3] containing 0.1% gelatin, 0.15 mM CaCl₂, and 1 mM MgCl₂) or GVB-Mg-EGTA (5 mM sodium Veronal-buffered saline [142 mM] [pH 7.3] containing 0.1% gelatin, 10 mM EGTA, and 10 mM MgCl₂), (iii) ¹²⁵I-labeled C3 sufficient to provide a specific activity of 50,000 cpm/µg of C3 for the mixture of labeled and unlabeled C3 in serum, and (iv) 6.0 x 10⁵ melanin ghosts or heat-killed cryptococcal cells. The tubes containing all of the reagents except melanin ghosts or cells were warmed for 5 min at 37°C, and the reaction was initiated by addition of the ghosts or cells. Duplicate 30-µl samples were then withdrawn at intervals of 1, 2, 4, 6, 8, 10, 12, 16, 20, and 25 min and placed into 150 µl of stop solution consisting of PBS with 0.1% sodium dodecyl sulfate and 20 mM EDTA. The melanin ghosts or cells were washed four times with PBS-0.1% sodium dodecyl sulfate by using Millipore (Bedford, Mass. USA) MABV-N12 filter plates fitted with BV 1.2-µm-pore-size filter membranes. The membranes were removed, and the amount of specifically bound C3 was determined by subtracting the radioactivity of samples that used heat-inactivated NHS from the total amount bound with NHS. Binding data are reported as the numbers of bound C3 molecules per melanin ghost or cryptococcal cell versus incubation time. For C. neoformans cells, C3 binding data were adjusted to the relative capsule size of cells grown in the presence or absence of L-DOPA to account for any differences in capsule size between the groups. Capsule sizes were determined by light microscopy by using an eyepiece with a grid with a 1-µm-mesh-size resolution. The data shown are representative of at least two replicate experiments for C. neoformans-derived melanin ghosts and from one experiment for A. niger-derived melanin ghosts.

Immunofluorescence (IF) analysis of C3 binding to melanin. C. neoformans-derived melanin ghosts (4 x 10⁵) were incubated in 40% NHS for 2, 4, 8, and 16 min as described above, with the exception that ¹²⁵I-C3 was not added to the reaction mixture. After the reaction was stopped, the melanin ghosts were washed three times with PBS, resuspended in 100 µl of a 1/25 dilution of fluorescein isothiocyanate (FITC)-conjugated antiserum to human C3 (Kent Laboratories, Inc., Redmond, Wash.) in PBS containing 1% bovine serum albumin (Sigma Chemical Co.), and incubated for 1 h at 0°C. The melanin ghosts were washed twice with PBS, suspended in 1 drop of Vectashield (Vector Laboratories, Inc., Burlingame, Calif.), applied to poly-L-lysine-coated slides (Sigma Chemical Co.), and allowed to settle overnight at room temperature. The pattern of C3 deposition was determined by epifluorescence microscopy with a Nikon Eclipse E800 microscope with an oil immersion lens objective of 100x. Images were collected at 0.4-µm distances with a Photonic Science (Millham, United Kingdom) integrating charge-coupled-device camera driven by Image Pro Plus version 3.0 image analysis software (Media Cybernetics, Silver Spring, Md.).

Immunohistochemical analysis of C3 binding to melanin. Five female BALB/c mice (6 to 8 weeks old) (National Cancer Institute, Rockville, Md.) were injected intratracheally with 10⁷ C. neoformans-derived melanin ghosts. Mice were killed 7 days after injection, and the lungs were collected for analysis. Tissue sections 4 µm thick were deparaffinized in xylenes and rehydrated by serial incubations in solutions with decreasing ethanol concentrations. The samples were blocked with SuperBlock blocking buffer (Pierce) for 4 h at room temperature to prevent nonspecific binding and then incubated with FITC-conjugated polyclonal goat anti-mouse C3 (ICN Pharmaceuticals, Inc., Aurora, Ohio) for 1.5 h at 37°C. As a control, melanin ghosts were incubated with FITC-conjugated polyclonal goat anti-mouse C3 as described above. The samples were washed with PBS, a mounting solution (50% glycerol and 0.1 M N-propyl gallate in PBS) and coverslips were applied to the slides, and the samples were examined with an Olympus America Inc. (Melville, N.Y.) AX70 microscope at a magnification of x250. Mice were housed in the animal facility at the Albert Einstein College of Medicine, and all experimental procedures adhered to protocols approved by the Animal Care and Use Committee.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Complement activation by melanin in vitro. Melanin ghosts were isolated from in vitro-melanized C. neoformans 24067 cells and A. niger J9901 conidia and then incubated in 40% NHS containing ¹²⁵I-labeled C3. Deposition of C3 fragments onto the melanin ghosts occurred as early as after 1 min of incubation, reaching maximum depositions of approximately 1.9 x 10⁶ C3 fragments per C. neoformans-derived melanin ghost after 12 min and 1.3 x 10⁶ C3 fragments per A. niger-derived melanin ghost after 25 min (Fig. 1). The treatment of NHS with EGTA, which prevents activation of the classical pathway by chelating Ca²⁺ (13, 31), did not affect the kinetics or total deposition of C3 fragments onto the melanin ghosts (data not shown), indicating that complement activation by melanins occurs solely through the alternative pathway. Comparisons between the classical and alternative pathways are difficult to make, however, because of the 10-fold-higher concentration of MgCl₂ used in the reaction mixture for alternative complement activation, which provided greater stability to the mixture. The concentration of MgCl₂ was increased to account for chelation by EGTA. IF analyses of C. neoformans-derived melanin ghosts incubated in NHS revealed that the initial deposition of C3 fragments occurred at discrete focal sites. The number of discrete focal sites increased with increased incubation time, but the distribution of C3 never reached confluence (Fig. 2). We did not use synthetic melanin in these studies, because synthetic melanin is usually made by incubating the precursor (e.g., L-DOPA) with chemical oxidants, such as H₂O₂, to increase the rate of polymerization into melanin. However, during the formation of synthetic melanin, these oxidants induce other modes of polymerization (33) as well as degradation of some of the key intermediates of the natural melanogenic pathway (37); therefore, the final product is likely to consist of a mixture of various polymerized structures. Thus, the commercially available synthetic melanin cannot be used as an adequate control for these studies. On the other hand, if chemical oxidants are not used, very large batches of reaction mixture (i.e., precursor in suspension) or a very long incubation time (over a year) would be required to yield enough melanin for use. In that event, there would be no guarantee that the synthetic product was the same as the material synthesized catalytically by the fungus.

View larger version (20K): [in this window] [in a new window]

FIG. 1. Complement activation by C. neoformans- and A. niger-derived melanin ghosts after incubation in 40% NHS containing 125I-labeled C3. Numbers of C3 molecules should be multiplied by 106.

View larger version (24K): [in this window] [in a new window]

FIG. 2. IF analysis of complement activation by C. neoformans-derived melanin ghosts after incubation in 40% NHS (magnification, x250).

Complement activation by melanin in vivo. Approximately 10⁷ C. neoformans-derived melanin ghosts were injected intratracheally into BALB/c mice to determine whether melanin ghosts could activate complement in murine tissue. IF analysis of lungs 7 days after injection demonstrated deposition of C3 fragments onto the melanin ghosts (Fig. 3A and B). Small granulomas were also observed surrounding the melanin ghosts (Fig. 3C).

View larger version (60K): [in this window] [in a new window]

FIG. 3. Light (A) and fluorescent (B) analyses of complement activation by C. neoformans-derived melanin ghosts in lung tissues of BALB/c mice (magnification, x250). (C) Hematoxylin and eosin staining of lung tissues of BALB/c mice, demonstrating the formation of small granulomas surrounding C. neoformans-derived melanin ghosts (magnification, x100). Arrows indicate melanin ghosts.

Kinetics of complement activation by melanized and nonmelanized C. neoformans in vitro. Melanized and nonmelanized C. neoformans 3501 cells were incubated in 40% NHS containing ¹²⁵I-labeled C3 to determine whether melanin could affect complement activation by cryptococcal cells. For both melanized and nonmelanized C. neoformans, deposition of readily measurable amounts of C3 fragments onto the cells occurred only after a lag of approximately 4 min, reaching a maximum of approximately 1.5 x 10⁷ C3 fragments per cell after 16 min of incubation (Fig. 4). No appreciable differences in the numbers of bound C3 fragments between melanized and nonmelanized cells were observed at any time period after the data were corrected to account for differences in capsule size between the melanized and nonmelanized cells.

View larger version (17K): [in this window] [in a new window]

FIG. 4. Complement activation by melanized and nonmelanized C. neoformans 3501 cells after incubation in 40% NHS containing 125I-labeled C3. Numbers of C3 molecules should be multiplied by 106.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Melanins are immunologically active molecules (1, 25, 27). Furthermore, melanization slightly increases the negative charge of C. neoformans cells (26) and affects their interaction with host effector cells (2, 37). These observations led us to explore the potential complement activation properties of melanins and whether melanization had an effect on complement activation by C. neoformans. Quantitative and IF analyses demonstrated that incubation of fungal melanins in NHS induced deposition of C3 fragments at numerous discrete focal sites that failed to become confluent over the surfaces of the melanin ghosts. This is an important qualitative difference from the pattern of C3 deposition observed with encapsulated and nonencapsulated C. neoformans cells, where deposition of C3 becomes confluent (21). The failure to deposit confluent C3 on the melanin ghosts may reflect a heterogenous surface and/or fundamental differences between the particles in the actions of the alternative pathway regulatory proteins factor H and factor I (30).

Approximately 1.9 x 10⁶ C3 fragments bound to each C. neoformans-derived melanin ghost after 12 min of incubation in NHS, whereas approximately 1.3 x 10⁶ C3 fragments bound to each A. niger-derived melanin after 25 min. The apparent difference in binding capacities may be due to the difference in size between the fungal melanins, as C. neoformans-derived melanin ghosts are approximately twice as large as A. niger-derived melanin ghosts (35) and therefore present a larger surface for the deposition of C3 fragments. IF analysis of murine lungs also demonstrated deposition of C3 fragments onto C. neoformans-derived melanin ghosts, indicating that melanins can activate the complement system in vivo.

Despite the ability of melanins to activate complement, the melanization of C. neoformans did not affect the kinetics or total deposition of C3 fragments onto the polysaccharide capsule of the cryptococcal cells. Melanin in C. neoformans is found in the cell wall (39), where it is shielded from the extracellular milieu by the polysaccharide capsule and therefore may not be able to interact with components of the complement system. The slight increase in negative charge in melanized cells may not be sufficient to significantly affect the interaction of the polysaccharide capsule with C3 molecules. Although we were unable to demonstrate a difference in levels of complement activation between melanized and nonmelanized cells, extracellular or cell wall-associated melanins produced by nonencapsulated pathogens may influence complement activation by the microbial surface. The interaction of exposed microbial melanins with the complement system may lead to complement depletion, which in turn may result in decreased susceptibility to complement-mediated phagocytosis by host effector cells. This would provide another mechanism for melanin in the virulence of microbial pathogens.

Recent studies have demonstrated that natural and synthetic melanins have anti-inflammatory properties (1, 25), which may be due to the ability of melanins to neutralize free radicals and oxidants (17, 23) and to suppress the production of proinflammatory cytokines (1, 25). The results from our study, however, indicate that melanins can activate the alternative complement pathway, suggesting a mechanism by which they can induce an inflammatory response. Complement activation by melanin particles would be expected to generate chemotactic and proinflammatory complement split products. In our studies, we noted that the injection of melanin into murine lungs elicited an inflammatory response, as indicated by the formation of small granulomas. Although these studies present contradictory properties for melanins, it is possible that the complex structures of these pigments allow for seemingly opposite roles. Our results suggest the possibility that other natural melanins, perhaps including human eumelanins, have the potential to activate complement in vivo. This ability would indicate a new biological activity for melanins which could contribute to the pathogenesis of several human autoimmune diseases and degenerative disorders.

 
A. Casadevall was supported by National Institutes of Health (NIH) grants AI33774, AI13342, and HL59842 and is a recipient of a Burroughs Wellcome Fund Scholar Award in Experimental Therapeutics. Á. L. Rosas was supported by NIH training grant 5T32GM07491. J. D. Nosanchuk was supported by NIH grant AI01489. T. R. Kozel and R. S. MacGill were supported by Public Health Service grant AI14209.

Á. L. Rosas and R. S. MacGill contributed equally to this work.

 
* Corresponding author. Mailing address: Albert Einstein College of Medicine, Golding 701, 1300 Morris Park Ave., Bronx, NY 10461. Phone: (718) 430-3766. Fax: (718) 430-8701. E-mail: nosanchu{at}aecom.yu.edu.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Avramidis, N., A. Kourounakis, L. Hadjipetrou, and V. Senchuk. 1998. Anti-inflammatory and immunomodulating properties of grape melanin: inhibitory effects on paw edema and adjuvant induced disease. Arzneim. -Forsch. 48:764–771.[Medline]
2
2. Blasi, E., R. Barluzzi, R. Mazzola, B. Tancini, S. Saleppico, M. Puliti, L. Pitzurra, and F. Bistoni. 1995. Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J. Neuroimmunol. 58:111–116.[CrossRef][Medline]
3
3. Broekhuyse, R. M., E. D. Kuhlman, and H. J. Winkens. 1992. Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp. Eye Res. 55:401–411.[CrossRef][Medline]
4
4. Broekhuyse, R. M., E. D. Kuhlman, and H. J. Winkens. 1993. Experimental autoimmune anterior uveitis (EAAU): induction by melanin antigen and suppresion by various treatments. Pigm. Cell Res. 6:1–6.[CrossRef][Medline]
5
5. Butler, M., and A. W. Day. 1998. Fungal melanins: a review. Can. J. Microbiol. 44:1115–1136.[CrossRef]
6
6. Davies, S. F., D. P. Clifford, J. R. Hoidal, and J. E. Repine. 1982. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J. Infect. Dis. 145:870–874.[Medline]
7
7. Diamond, R. D., J. E. May, M. Kane, M. M. Frank, and J. E. Bennet. 1973. The role of late complement components and the alternate complement pathway in experimental cryptococcosis. Proc. Soc. Exp. Biol. Med. 144:312–315.[CrossRef][Medline]
8
8. Diamond, R. D., J. E. May, M. Kane, M. M. Frank, and J. E. Bennet. 1974. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112:2260–2270.[Abstract/Free Full Text]
9
9. d’Ischia, M., and G. Prota. 1997. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson’s disease: a critical update. Pigm. Cell Res. 10:370–376.[CrossRef][Medline]
10
10. Doering, T. L., J. D. Nosanchuk, W. K. Roberts, and A. Casadevall. 1999. Melanin as a potential cryptococcal defence against microbicidal proteins. Med. Mycol. 37:175–181.[CrossRef][Medline]
11
11. Emery, H. S., C. P. Shelburne, J. P. Bowman, P. G. Fallon, C. A. Schulz, and E. S. Jacobson. 1994. Genetic study of oxygen resistance and melanization in Cryptococcus neoformans. Infect. Immun. 62:5694–5697.[Abstract/Free Full Text]
12
12. Enochs, W. S., T. Sarna, L. Zecca, P. A. Riley, and H. M. Swartz. 1994. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson’s disease: a hypothesis. J. Neural Transm. 7:83–100.
13
13. Fine, D. P., S. R. Marney, Jr., D. G. Colley, J. S. Sergent, and R. M. Des Prez. 1972. C3 shunt activation in human serum chelated with EGTA. J. Immunol. 109:807–809.[Abstract/Free Full Text]
14
14. Hill, H. Z. 1991. Melanins in the photobiology of skin cancer and the radiobiology of melanomas, p.31–53. In S. H. Wilson (ed.), Cancer biology and biosynthesis. Telford Press, Caldwell, N.J.
15
15. Jacobson, E. S., and H. S. Emery. 1991. Catecholamine uptake, melanization, and oxygen toxicity in Cryptococcus neoformans. J. Bacteriol. 173:401–403.[Abstract/Free Full Text]
16
16. Jacobson, E. S., N. D. Jenkins, and J. M. Todd. 1994. Relationship between superoxide dismutase and melanin in a pathogenic fungus. Infect. Immun. 62:4085–4086.[Abstract/Free Full Text]
17
17. Jacobson, E. S., and S. B. Tinnell. 1993. Antioxidant function of fungal melanin. J. Bacteriol. 175:7102–7104.[Abstract/Free Full Text]
18
18. Kaya, M., D. P. Edward, H. Tessler, and R. L. Hendricks. 1992. Augmentation of intraocular inflammation by melanin. Investig. Ophthalmol. Vis. Sci. 33:522–531.[Abstract/Free Full Text]
19
19. Kozel, T. R., B. Highison, and C. J. Stratton. 1984. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect. Immun. 43:574–579.[Abstract/Free Full Text]
20
20. Kozel, T. R., G. S. T. Pfrommer, A. S. Guerlain, B. A. Highison, and G. J. Highison. 1988. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3. Infect. Immun. 56:2794–2800.[Abstract/Free Full Text]
21
21. Kozel, T. R., M. A. Wilson, and J. W. Murphy. 1991. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59:3101–3110.[Abstract/Free Full Text]
22
22. Langhof, H., M. Feuerstein, and G. Schabinski. 1965. Melaninantikorperbildung bei Vitiligo. Hautarzt 16:209–212.
23
23. Longuet-Higgins, H. C. 1960. On the origin of the free radical properties of melanins. Arch. Biochem. Biophys. 86:231–232.
24
24. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515–548.[Abstract]
25
25. Mohagheghpour, N., N. Waleh, S. J. Garger, L. Dousman, L. K. Grill, and D. Tusé. 2000. Synthetic melanin suppresses production of proinflammatory cytokines. Cell. Immunol. 199:25–36.[CrossRef][Medline]
26
26. Nosanchuk, J. D., and A. Casadevall. 1997. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect. Immun. 65:1836–1841.[Abstract]
27
27. Nosanchuk, J. D., A. L. Rosas, and A. Casadevall. 1998. The antibody response to fungal melanin in mice. J. Immunol. 160:6026–6031.[Abstract/Free Full Text]
28
28. Nosanchuk, J. D., A. L. Rosas, S. C. Lee, and A. Casadevall. 2000. Melanisation of Cryptococcus neoformans in human brain tissue. Lancet 355:2049–2050.[CrossRef][Medline]
29
29. Nosanchuk, J. D., P. Valadon, M. Feldmesser, and A. Casadevall. 1999. Melanization of Cryptococcus neoformans in murine infection. Mol. Cell. Biol. 19:745–750.[Abstract/Free Full Text]
30
30. Pangburn, M. K., and H. J. Müller-Eberhard. 1984. The alternative pathway of complement. Springer Semin. Immunopathol. 7:163–192.[CrossRef][Medline]
31
31. Platts-Mills, T. A. E., and K. Ishizaka. 1974. Activation of the alternative pathway of human complement by rabbit cells. J. Immunol. 113:348–357.[Abstract/Free Full Text]
32
32. Polacheck, I., Y. Platt, and J. Aronovitch. 1990. Catecholamines and virulence of Cryptococcus neoformans. Infect. Immun. 58:2919–2922.[Abstract/Free Full Text]
33
33. Prota, G. 1988. Progress in the chemistry of melanins and related metabolites. Med. Res. Rev. 8:525–556.[Medline]
34
34. Riley, P. A. 1991. Melanogenesis: a realistic target for antimelanoma therapy? Eur. J. Cancer 27:1172–1177.
35
35. Rosas, Á. L., J. D. Nosanchuk, B. L. Gómez, W. A. Edens, J. M. Henson, and A. Casadevall. 2000. Isolation and serological analyses of fungal melanins. J. Immunol. Methods 244:69–80.[CrossRef][Medline]
36
36. Rosas, Á. L., J. D. Nosanchuk, M. Feldmesser, G. M. Cox, H. C. McDade, and A. Casadevall. 2000. Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect. Immun. 68:2845–2853.[Abstract/Free Full Text]
37
37. Stravs-Mombelli, L., and H. Willer. 1985. Reinvestigation of the formation of dopa-melanin: new aspects of the autoxidation of dopa, p.69. In J. Bargnara, S. N. Klaus, F. Paul, and M. Schartl (ed.), Pigment cell: biological, molecular and clinical aspects of pigmentation. University of Tokyo Press, Tokyo, Japan.
38
38. Tack, B. F., J. Janatova, M. L. Thomas, R. A. Harrison, and C. H. Hammer. 1981. The third, fourth, and fifth components of human complement: isolation and biochemical properties. Methods Enzymol. 80:64–101.[CrossRef]
39
39. Wang, Y., P. Aisen, and A. Casadevall. 1995. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect. Immun. 63:3131–3136.[Abstract]
40
40. Wang, Y., P. Aisen, and A. Casadevall. 1996. Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect. Immun. 64:2420–2424.[Abstract]
41
41. Wang, Y., and A. Casadevall. 1994. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob. Agents Chemother. 38:2648–2650.[Abstract/Free Full Text]
42
42. Wang, Y., and A. Casadevall. 1994. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect. Immun. 62:3004–3007.[Abstract/Free Full Text]
43
43. Wasserman, H. P., and J. J. Van Der Walt. 1973. Antibodies against melanin: the significance of negative results. S. Afr. Med. J. 47:79.
44
44. Wheeler, M., and A. A. Bell. 1988. Melanins and their importance in pathogenic fungi. Curr. Top. Med. Mycol. 2:338–387.[Medline]
45
45. Youdim, M. B., D. Ben-Shachar, and P. Riederer. 1994. The enigma of neuromelanin in Parkinson’s disease substantia nigra. J. Neural Transm. 43:113–122.[CrossRef]

---

Clinical and Diagnostic Laboratory Immunology, January 2002, p. 144-148, Vol. 9, No. 1
1071-412X/01/$04.00+0     DOI: 10.1128/CDLI.9.1.144-148.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Gaitanis, G., Chasapi, V., Velegraki, A. (2005). Novel Application of the Masson-Fontana Stain for Demonstrating Malassezia Species Melanin-Like Pigment Production In Vitro and in Clinical Specimens. J. Clin. Microbiol. 43: 4147-4151 [Abstract] [Full Text]  
• Mednick, A. J., Nosanchuk, J. D., Casadevall, A. (2005). Melanization of Cryptococcus neoformans Affects Lung Inflammatory Responses during Cryptococcal Infection. Infect. Immun. 73: 2012-2019 [Abstract] [Full Text]  
• Dadachova, E., Nosanchuk, J. D., Shi, L., Schweitzer, A. D., Frenkel, A., Nosanchuk, J. S., Casadevall, A. (2004). Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc. Natl. Acad. Sci. USA 101: 14865-14870 [Abstract] [Full Text]  
• Alviano, D. S., Franzen, A. J., Travassos, L. R., Holandino, C., Rozental, S., Ejzemberg, R., Alviano, C. S., Rodrigues, M. L. (2004). Melanin from Fonsecaea pedrosoi Induces Production of Human Antifungal Antibodies and Enhances the Antimicrobial Efficacy of Phagocytes. Infect. Immun. 72: 229-237 [Abstract] [Full Text]  
• Nosanchuk, J. D., Casadevall, A. (2003). Budding of melanized Cryptococcus neoformans in the presence or absence of L-dopa. Microbiology 149: 1945-1951 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosas, A. L. Articles by Casadevall, A. Search for Related Content PubMed PubMed Citation Articles by Rosas, A. L. Articles by Casadevall, A.